It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
Fortis will assume complete operational and financial control, allowing it to consolidate the hospital's performance within its network
Facility designed to advance the next generation of imaging systems
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
Replicate will receive research funding and could potentially receive up to approximately US$550 million
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Subscribe To Our Newsletter & Stay Updated
